Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 2 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  2. US 12018260

    Tunable Reversir™ compounds

    Alnylam Pharmaceuticals, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  3. US 12005074

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  4. US 11987792

    Compositions and methods for inhibiting expression of the LECT2 gene

    Alnylam Pharmaceuticals, Inc. · Granted May 21, 2024 · Expires May 16, 2044

    granted
  5. US 11965166

    Complement factor B (CFB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  6. US 11959081

    Transthyretin (TTR) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  7. US 11944687

    Carbohydrate conjugate RNA agents and process for their preparation

    Alnylam Pharmaceuticals, Inc. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  8. US 11926832

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  9. US 11884919

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11873491

    Complement component C5 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted
  11. US 11866701

    Complement component C3 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  12. US 11866709

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  13. US 11866710

    Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  14. US 11859185

    Glucokinase (GCK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  15. US 11840692

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  16. US 11834662

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  17. US 11827883

    Dosages and methods for delivering lipid formulated nucleic acid molecules

    Alnylam Pharmaceuticals, Inc. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  18. US 11806360

    Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

    Alnylam Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  19. US 11725209

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  20. US 11725207

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  21. US 11685918

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  22. US 11679158

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  23. US 11666653

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  24. US 11649459

    Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases

    Alnylam Pharmaceuticals, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted